Advertisement
U.S. Markets closed

Day One Biopharmaceuticals, Inc. (DAWN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
15.08+0.07 (+0.47%)
At close: 04:00PM EDT
15.08 0.00 (0.00%)
After hours: 04:56PM EDT
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
8,192
0
0
0
0
-
Operating Expense
300,014
206,064
146,909
72,743
13,782
-
Operating Income
-292,529
-206,064
-146,909
-72,743
-13,782
-
Net Non Operating Interest Income Expense
-
-
4,746
4
-30
-2,077
Other Income Expense
126,601
17,147
4,728
-11
-30,031
-
Pretax Income
-165,928
-188,917
-142,181
-72,754
-43,843
-
Net Income Common Stockholders
-167,480
-188,917
-142,181
-170,639
-40,507
-
Diluted NI Available to Com Stockholders
-167,480
-188,917
-142,181
-170,639
-40,507
-
Basic EPS
-2.29
-2.37
-2.17
-4.62
-0.96
-
Diluted EPS
-2.29
-2.37
-2.17
-4.62
-0.96
-
Basic Average Shares
76,086
79,773
65,467
36,961
42,031
-
Diluted Average Shares
76,086
79,773
65,467
36,961
42,031
-
Total Operating Income as Reported
-292,529
-206,064
-146,909
-72,743
-13,782
-
Total Expenses
300,721
206,064
146,909
72,743
13,782
-
Net Income from Continuing & Discontinued Operation
-167,480
-188,917
-142,181
-70,645
-40,507
-
Normalized Income
-186,122
-206,104
-146,927
-70,649
-10,507
-
Interest Expense
-
-
-
-
30
2,077
Net Interest Income
-
-
4,746
4
-30
-2,077
EBIT
-292,529
-206,064
-146,909
-72,743
-13,782
-
EBITDA
-291,803
-205,681
-146,378
-72,544
-13,627
-
Reconciled Depreciation
726
383
531
199
155
-
Net Income from Continuing Operation Net Minority Interest
-167,480
-188,917
-142,181
-70,645
-40,507
-
Total Unusual Items Excluding Goodwill
18,642
17,187
4,746
4
-30,000
-
Total Unusual Items
18,642
17,187
4,746
4
-30,000
-
Normalized EBITDA
-310,445
-222,868
-151,124
-72,548
16,373
-
Tax Rate for Calcs
0
0
0
0
0
-
Tax Effect of Unusual Items
0
0
0
0
0
-